Impact of the publication of the Italian guidelines for bronchiolitis on the management of hospitalized children in Pisa, Italy

Pediatr Pulmonol. 2023 Aug;58(8):2267-2274. doi: 10.1002/ppul.26460. Epub 2023 May 8.

Abstract

Bronchiolitis represents one of the major causes of hospitalization and mortality in children younger than 1 year, but its management continues to be heterogenous both in those who are hospitalized and in those who are not. To assess the impact of the publication of the Italian guidelines on bronchiolitis in October 2014, we analyzed data from children aged ≤12 months admitted for bronchiolitis at the University Hospital of Pisa from January 2010 to December 2019, dividing them into two groups based on whether admission was either preceding (Group 1) or following (Group 2) the publication of the guidelines. 346 patients (mean age 4.1 ± 2.8 months, 55% males) were admitted in the study period; 43.3%, 49.4%, and 7.3% of patients had mild, moderate or severe bronchiolitis, respectively. The mean length of hospital stay was 6.7 ± 2.9 days; 90.5% of the patients underwent nasal swab and 200 patients tested positive for RSV (in mono or coinfection with other viruses). We found no difference in RSV prevalence and severity distribution between the two groups, while we observed a significant reduction in the use of both chest X-rays (66.9% vs. 34.8%, p < 0.001), blood testing (93.4% vs. 58.2%, p < 0.001) and inhaled or systemic corticosteroids (93.1% vs. 47.8%, p < 0.001) in Group 2. No significant reduction in the use of antibiotics and of inhaled β2 agonists was found. Our data suggest that the publication of the Italian guidelines for bronchiolitis has contributed to improving the management of patients admitted for bronchiolitis in our Unit.

Keywords: RSV; high flow nasal cannula; infants; rhinovirus; wheezing.

MeSH terms

  • Bronchiolitis* / epidemiology
  • Bronchiolitis* / therapy
  • Child
  • Child, Hospitalized
  • Female
  • Hospitalization
  • Humans
  • Infant
  • Italy / epidemiology
  • Male
  • Respiratory Syncytial Virus Infections* / epidemiology

Grants and funding